Simple Clinical Tools to Predict Decompensation in Patients With Compensated Cirrhosis: An Unmet Need
- PMID: 31004761
- PMCID: PMC11090165
- DOI: 10.1016/j.cgh.2019.04.026
Simple Clinical Tools to Predict Decompensation in Patients With Compensated Cirrhosis: An Unmet Need
Conflict of interest statement
Conflicts of interest
The authors disclose no conflicts.
Figures

Comment on
-
Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation.Clin Gastroenterol Hepatol. 2019 Oct;17(11):2330-2338.e1. doi: 10.1016/j.cgh.2019.01.042. Epub 2019 Feb 1. Clin Gastroenterol Hepatol. 2019. PMID: 30716478
Similar articles
-
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria.Hepatol Int. 2022 Feb;16(1):89-98. doi: 10.1007/s12072-021-10280-w. Epub 2022 Jan 24. Hepatol Int. 2022. PMID: 35072932
-
Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.J Hepatol. 2021 Sep;75(3):589-599. doi: 10.1016/j.jhep.2021.04.022. Epub 2021 Apr 24. J Hepatol. 2021. PMID: 33905794 Clinical Trial.
-
Thick Fibrous Septa on Liver Biopsy Specimens Predict the Development of Decompensation in Patients With Compensated Cirrhosis.Am J Clin Pathol. 2021 Oct 13;156(5):802-809. doi: 10.1093/ajcp/aqab024. Am J Clin Pathol. 2021. PMID: 33940622 Free PMC article.
-
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.J Hepatol. 2022 Oct;77(4):1014-1025. doi: 10.1016/j.jhep.2022.05.021. Epub 2022 May 31. J Hepatol. 2022. PMID: 35661713
-
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.Clin Ther. 2010 Dec;32(13):2117-38. doi: 10.1016/S0149-2918(11)00022-1. Clin Ther. 2010. PMID: 21316532 Review.
Cited by
-
Preventing the progression of cirrhosis to decompensation and death.Nat Rev Gastroenterol Hepatol. 2025 Apr;22(4):265-280. doi: 10.1038/s41575-024-01031-x. Epub 2025 Jan 27. Nat Rev Gastroenterol Hepatol. 2025. PMID: 39870944 Review.
-
Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab-based model.Hepatol Commun. 2022 Dec;6(12):3324-3334. doi: 10.1002/hep4.2091. Epub 2022 Oct 10. Hepatol Commun. 2022. PMID: 36214066 Free PMC article. Clinical Trial.
-
Six-minute walk test predicts future decompensation in patients with compensated liver cirrhosis.Rev Assoc Med Bras (1992). 2022 Aug;68(8):991-994. doi: 10.1590/1806-9282.20210733. Rev Assoc Med Bras (1992). 2022. PMID: 36134826 Free PMC article. No abstract available.
References
-
- Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65:310–335. - PubMed
-
- Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133:481–488. - PubMed
-
- Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 2018;155:1140–1153. - PubMed
-
- Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012;56:1439–1447. - PubMed
-
- Robic MA, Procopet B, Metivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011;55:1017–1024. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical